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MaBACKGROUND Low ﬂow (LF) can occur with reduced (classic) or preserved (paradoxical) left ventricular ejection
fraction (LVEF).
OBJECTIVES The objective of this study was to compare outcomes of patients with low ejection fraction (LEF),
paradoxical low ﬂow (PLF), and normal ﬂow (NF) after aortic valve replacement (AVR).
METHODS We examined 1,154 patients with severe aortic stenosis (AS) who underwent AVR with or without coronary
artery bypass grafting.
RESULTS Among these patients, 206 (18%) had LEF as deﬁned by LVEF of <50%; 319 (28%) had PLF as deﬁned by
LVEF of$50% but stroke volume indexed to body surface area (SVi) of #35 ml ∙m2; and 629 (54%) had NF, as deﬁned
by LVEF of $50% and SVi of >35 ml ∙ m2. Aortic valve area was lower in low ﬂow/LVEF groups (LEF: 0.71  0.20 cm2
and PLF: 0.65  0.23 cm2 vs. NF: 0.77  0.18 cm2; p < 0.001). The 30-day mortality was higher (p < 0.001) in LEF and
PLF groups than in the NF group (6.3% and 6.3% vs. 1.8%, respectively). SVi and PLF group were independent predictors
of operative mortality (odds ratio [OR]: 1.18, p < 0.05; and OR: 2.97, p ¼ 0.004; respectively). At 5 years after AVR,
overall survival was 72  4% in LEF group, 81  2% in PLF group, and 85  2% in NF group (p < 0.0001).
CONCLUSIONS Patients with LEF or PLF AS have a higher operative risk, but pre-operative risk score accounted only for
LEF and lower LVEF. Patients with LEF had the worst survival outcome, whereas patients with PLF and normal ﬂow had
similar survival rates after AVR. As a major predictor of perioperative mortality, SVi should be integrated in AS patients’
pre-operative evaluation. (J Am Coll Cardiol 2015;65:645–53) © 2015 by the American College of Cardiology Foundation.L ow ﬂow in aortic stenosis (AS) can occur withreduced or preserved left ventricular ejectionfraction (LVEF), which are named classic and
paradoxical low ﬂow, respectively. Because the
transvalvular pressure gradient is highly ﬂow depen-
dent, these clinical conditions are often associated
with low gradient, which adds complexity to the
assessment of stenosis severity and therapeutic de-
cision making. According to current American Col-
lege of Cardiology/American Heart Association
(ACC/AHA) guidelines (1), aortic valve replacement
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AVR ¼ aortic valve replacement
graft.
ABBR EV I A T I ON S
AND ACRONYMS
AS = aortic stenosis
AVR = aortic valve
replacement
CABG = coronary artery
bypass graft
LEF = low ejection fraction
LV = left ventricular
LVEF = left ventricular
ejection fraction
NF = normal ﬂow
NYHA = New York Heart
Association
PLF = paradoxical low ﬂow
SVi = stroke volume index
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646compare perioperative outcomes among pa-
tients with LEF, PLF, and NF AS.
METHODS
STUDY POPULATION. Among 1,984 consec-
utive patients who underwent AVR with or
without coronary artery bypass graft (CABG)
as their ﬁrst open-heart surgery in our insti-
tution between 2002 and 2010, we included
1,154 patients with calciﬁc severe AS (as
deﬁned by a mean gradient $40 mm Hg, a
peak aortic jet velocity $4 m ∙ s1, an aortic
valve area #1.0 cm2, or an indexed aortic
valve area #0.6 cm2 ∙ m2) (Figure 1). Data
were prospectively collected and stored in an
electronic database.SEE PAGE 654Patients for whom primary indication for AVR was
aortic insufﬁciency or CABG and patients with an
incomplete echocardiographic evaluation in the 3
months before AVR were excluded.
ECHOCARDIOGRAPHY. Doppler echocardiographic mea-








245: concomitant aortic surgery
556: Multi-valve surgery
226: Previous Open Heart Surgery  
352: Incomplete/unavailable Echocardiography
478: Non severe AS (primary indication for AVR:
        CABG, aortic insufficiency, endocarditis...)
; AS ¼ aortic stenosis; CABG ¼ coronary artery bypassrecommendations of the American Society of Echo-
cardiography: LVEF calculated by the biplane Simp-
son method, the peak aortic jet velocity, the peak and
mean transvalvular pressure gradients obtained with
the use of the modiﬁed Bernoulli equation, and the
aortic valve area obtained with the use of the stan-
dard continuity equation (7). Doppler echocardio-
graphic measurement of LV outﬂow tract stroke
volume was corroborated by the 2-dimensional (2D)
volumetric method.
Our population was divided into 3 groups depend-
ing on the values of LVEF and SVi: the NF group,
deﬁned as LVEF $50% and SVi >35 ml ∙ m2; the PLF
group, deﬁned as LVEF $50% and SVi #35 ml ∙ m2;
and the LEF group, deﬁned as LVEF <50%.
CORONARY ANGIOGRAPHY. All patients underwent
coronary angiography as part of the pre-operative
evaluation. The severity of coronary artery disease
was assessed by angiographic Duke myocardial jeop-
ardy score, which expresses how many of the 6 cor-
onary arterial segments are jeopardized by signiﬁcant
(>70% estimated luminal area reduction) stenoses
(8). Two points are added to the score for each jeop-
ardized segment.
STUDY ENDPOINTS. Primary endpoints for this study
were 30-day mortality and long-term mortality.
Secondary endpoints were: 1) perioperative major
cardiovascular nonfatal events consisting of atrial
ﬁbrillation/ﬂutter, ventricular tachycardia/ﬁbrillation,
cardiac arrest, low output syndrome, acute cardiac
failure, intra-aortic balloon pump application, multi-
organ failure and ischemic event; 2) perioperative
noncardiac, nonfatal events consisting of respiratory
intubation (intubation time period longer than 48 h
and reintubation), renal (hemodialysis/ﬁltration and
increase in blood level rate of creatinine higher than
100 mmol ∙ l1), and neurological (stroke and transient
ischemic accident) events; 3) length of time of vaso-
trope/inotrope use; 4) intensive care unit length of
stay; and 5) hospital length of stay.
Perioperative events and deaths were prospec-
tively collected. Late mortality data were retrospec-
tively obtained from Quebec Institute of Statistics. To
maximize the interrogation of the central Quebec
Institute of Statistics database, a list with multiple
demographics (including ﬁrst and last names, dates of
birth, and social security numbers) and a delay of
1 year between interrogation and closing follow-up
dates were used.
STATISTICAL ANALYSIS. Results are mean  SD or
percentages. For continuous variables, differences
between groups were analyzed with the use of 1-way
ANOVA, followed by the Tukey post-hoc test for
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Adjusted Cox Survival Curves
1.8%
Clavel, M-A. et al. J Am Coll Cardiol. 2015; 65(7):645–53.
Prevalence for patient groups, 30-day mortality, and overall survival in normal ﬂow (red line), paradoxical low ﬂow (blue line), and low ejection fraction (orange line)
patients. Survival is shown by Cox survival curves adjusted for age, female sex, New York Heart Association functional class III or IV, atrial ﬁbrillation, chronic kidney
failure, diabetes, coronary artery disease, chronic obstructive pulmonary disease, left ventricular mass index, and mean gradient.
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647intergroup comparisons. The chi-square or the Fisher
exact test was used to compare categorical variables
as appropriate. The association between periproce-
dural (30-day) mortality and risk factors was exam-
ined by logistic regression analysis and are
presented as odds ratio (OR, 95% conﬁdence interval
[CI], and p value). Multivariate analysis of periproce-
dural mortality was analysed by stepwise backward
models. Effects of the clinical and Doppler echocar-
diographic variables on overall survival were assessed
using Cox proportional hazard models and are pre-
sented as hazard ratios (HR, 95% CI, and p value).
A p value of <0.05 was considered statisticallysigniﬁcant. All variables with a p value of <0.05 in
univariate analysis were entered in multivariate
models. All variables in the Cox models veriﬁed the
proportional hazards assumption on the basis of
inspection of trends in the Schoenfeld residuals (all
p > 0.15). Statistical analyses were performed with
JMP version 9.1 and SPSS version 20.0 software (IBM,
Armonk, New York).
RESULTS
BASELINE CHARACTERISTICS. Among the 1,154 pa-
tients included in the study, 629 (54%) were in the NF
TABLE 1 Baseline Characteristics
NF Group
(n ¼ 629; 54%)
PLF Group
(n ¼ 319; 28%)
LEF Group
(n ¼ 206; 18%) p Value
Clinical data
Age, yrs 69  10 70  10 71  10 0.19
Females 239 (38)* 132 (41)* 53 (26)†‡ 0.0007
Body surface area, m2 1.81  0.20*† 1.84  0.23‡ 1.85  0.21‡ 0.005
Systolic blood pressure, mm Hg 130  21* 127  19 123  19‡ 0.001
Diastolic blood pressure, mm Hg 70  10† 73  11*‡ 71  10† 0.0002
Heart rate, beat/min 65  11*† 72  13‡ 73  15‡ <0.0001
NYHA functional class III-IV 221 (35)*† 143 (45)*‡ 109 (53)†‡ <0.0001
Hypertension 439 (70) 225 (71) 141 (68) 0.88
Diabetes 163 (26)* 100 (31) 77 (37)‡ 0.006
COPD 80 (13)* 48 (15)* 60 (29)†‡ <0.0001
CAD 298 (47)* 162 (51)* 144 (70)†‡ <0.0001
Myocardial Duke jeopardy score 1.56  2.97* 1.82  3.21* 3.39  4.21†‡ <0.0001
Previous myocardial infarction 97 (16)* 58 (18)* 82 (40)†‡ <0.0001
Chronic kidney disease 41 (7)* 26 (8)* 38 (18)†‡ <0.0001
Parsonnet risk score, % 3.8  3.6* 4.4  4.3* 8.7  10.9†‡ <0.0001
Echocardiographic data
LV end diastolic diameter, cm 4.71  0.58*† 4.57  0.56*‡ 5.35  0.83†‡ <0.0001
LV end diastolic volume, ml 105  31*† 98  28*‡ 143  51†‡ <0.0001
Relative wall thickness ratio 0.52  0.11*† 0.54  0.13*‡ 0.46  0.12†‡ <0.0001
LV mass index, g ∙ m2 122  34*† 115  33*‡ 146  45†‡ <0.0001
Peak aortic jet velocity, m ∙ s1 4.3  0.7*† 4.0  0.8*‡ 3.7  0.8†‡ <0.0001
Mean gradient, mm Hg 45  15*† 42  17*‡ 36  16†‡ <0.0001
Aortic valve area, cm2 0.77  0.18*† 0.65  0.23*‡ 0.71  0.20†‡ <0.0001
Indexed aortic valve area,
cm2 ∙ m2
0.43  0.09*† 0.35  0.13*‡ 0.38  0.10†‡ <0.0001
Stroke volume, ml 77  15*† 56  10*‡ 59  16†‡ <0.0001
Stroke volume index, ml ∙ m2 43  7*† 30  4*‡ 32  8†‡ <0.0001
LV ejection fraction, % 65  8*† 62  7*‡ 35  9†‡ <0.0001
Values are mean  SD or n (%). *Different from LEF. †Different from PLF. ‡Different from NF.
CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; LEF ¼ low ejection fraction;
LV ¼ left ventricular; NF ¼ normal ﬂow; NYHA ¼ New York Heart Association; PLF ¼ paradoxical low ﬂow.
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648group, 319 (28%) were in the PLF group, and 206
(18%) were in the LEF group (Central Illustration). Age
was similar among the 3 groups. Patients in the LEF
group were more often male; had more incidence
of chronic obstructive pulmonary disease, chronic
kidney disease, coronary artery disease, previous
myocardial infarction, and a more severe burden of
coronary artery disease (as documented by the Duke
myocardial jeopardy score) and thus a higher surgical
risk as estimated by the Parsonnet score (9) than the
2 other groups (Table 1, Central Illustration). Baseline
clinical data were similar between PLF and NF groups,
and accordingly, the risk of operative death predicted
by the Parsonnet score was equivalent in both the
PLF and NF patients. With regard to echocardio-
graphic data, PLF patients had more pronounced LV
concentric remodeling (smaller LV cavity size and
higher relative wall thickness) and, a priori, more
severe AS (with a smaller aortic valve area and
comparable mean gradient) and lower LVEF whileremaining in the normal range than NF patients. As
expected, PLF patients had a lower stroke volume
and SVi than NF patients, comparable to that of LEF
patients, even if LVEF was preserved (Table 1).
PREDICTORS OF 30-DAY MORTALITY. Forty-four
patients (3.8%) died within 30 days following AVR.
These deaths occurred for 13 patients (6.3%) in the
LEF group, 20 patients (6.3%) in the PLF group, and 11
patients (1.8%) in the NF group (p < 0.0001) (Central
Illustration, Table 2). When observed 30-day mortal-
ity was compared with predicted 30-day mortality,
the Parsonnet risk score explained the excess of
mortality in LEF patients but not in PLF patients
(Figure 2).
In univariate analysis, variables associated with
increased risk of 30-day mortality were older age
(p ¼ 0.007), female sex (p ¼ 0.002), New York Heart
Association (NYHA) functional class III and IV
(p < 0.0001), diabetes (p ¼ 0.004), coronary artery
disease (p ¼ 0.01), Duke myocardial jeopardy score
(p ¼ 0.0003), previous myocardial infarction
(p ¼ 0.005), chronic obstructive pulmonary dis-
ease (p ¼ 0.03), chronic kidney disease (p ¼ 0.02),
Parsonnet score (p < 0.0001), smaller aortic valve
area (p ¼ 0.05), lower mean gradient (p ¼ 0.04), lower
peak aortic jet velocity (p ¼ 0.03), lower SVi
(p ¼ 0.0003), lower LVEF (p ¼ 0.003), LEF group
(p < 0.001), and PLF group (p < 0.0001) (Table 3).
After adjustment for age, sex, Parsonnet risk
score, NYHA functional class III to IV, and Duke
myocardial jeopardy score, PLF group remained an
independent predictor of 30-day mortality (OR: 2.97;
95% CI: 1.40 to 6.60; p ¼ 0.004) whereas LEF did not
(p ¼ 0.28) (Table 3, Model 1). When entering SVi and
LVEF as continuous variables in place of ﬂow groups
into the multivariate model, SVi (OR: 1.18; 95%
CI: 1.01 to 1.36 per 5 ml ∙ m2 decrease; p ¼ 0.05) was
an independent predictor of 30-day mortality
whereas LVEF was not (p ¼ 0.82) (Table 3, Model 2).
Among the 206 LEF patients, 71 had a normal ﬂow
(SVi >35 ml/m2). In this LEF subset, the operative
mortality rates of low ﬂow versus normal ﬂow were
similar (OR: 1.81; 95% CI: 0.48 to 6.81; p ¼ 0.36).
PERIOPERATIVE EVENTS. With regard to periopera-
tive cardiovascular events, low output syndrome and
the use of intra-aortic balloon pump were more
frequent in the low ﬂow and LEF groups than in the
NF group (all p < 0.0001). Accordingly, the length
of use of vasopressor or inotrope and the occurrence
of intubation longer than 48 h were higher in the
low ﬂow and LEF groups (Table 2). Acute cardiac
decompensation and multiorgan failure followed the
same trend but did not reach statistical signiﬁcance











278 (44)* 150 (47)* 114 (55)†‡ 0.004
Clamp time, min 78  29 81  33 81  35 0.42
Bypass time, min 104  37 106  43 109  48 0.19
Event
30-day mortality 11 (1.8)*† 20 (6.3)‡ 13 (6.3)‡ 0.0003
Cardiovascular events
Atrial ﬁbrillation/ﬂutter 296 (47) 167 (52) 111 (54) 0.13
Ventricular arrhythmia 32 (5.1) 13 (4.1) 13 (6.3) 0.52
Acute ischemic event 1 (0.2) 1 (0.3) 1 (0.5) 0.73
Cardiac arrest 10 (1.6) 6 (1.9) 3 (1.5) 0.92
Low output syndrome 29 (5)*† 31 (10)*‡ 32 (16)†‡ <0.0001
Acute cardiac failure 8 (1.3) 6 (1.9) 7 (3.4) 0.18
Intra-aortic balloon pump 8 (0.8)*† 9 (2.8)*‡ 17 (8.3)†‡ <0.0001
Multi-organ failure 4 (0.6) 5 (1.6) 4 (1.9) 0.21
Composite cardiac events
(except for arrhythmias)§
41 (7)*† 38 (12)*‡ 44 (21)†‡ <0.0001
Respiratory events
Intubation >48 h 21 (3.3)*† 22 (6.9)‡ 15 (7.3)‡ 0.01
Reintubation 23 (3.7)† 23 (7.2)‡ 10 (4.9) 0.05
Neurologic events
Stroke/transient ischemic attack 13 (2.1) 15 (4.7) 8 (3.9) 0.07
Renal events
Hemodialysis/ﬁltration 14 (2.2) 7 (2.2) 10 (4.9) 0.15
Increase in creatinine
>100 mmol ∙ l1
49 (7.8) 15 (4.7) 16 (7.8) 0.16
Laboratory data
Peak troponin I, mg ∙ l1 52  71 36  38 56  77 0.17
Peak troponin T, mg ∙ l1 0.81  087 0.83  1.65 0.85  0.94 0.93
Peak CKMB, mg ∙ m1 l 46  61 40  42 45  56 0.29
Length of hospital stay/medications
Hospitalization, days 8.8  8.7* 9.8  9.4 10.4  9.4‡ 0.04
Intensive care unit, h 59  130 64  129 68  93 0.60
Vasotrope/inotrope use, h 15  17*† 20  23*‡ 28  27†‡ <0.0001
Values are n (%) or mean  SD. *Different from low ejection fraction group. †Different from paradoxical low ﬂow
group. ‡Different from normal ﬂow group. §Composite event was calculated by at least one of the following:
acute ischemic event, cardiac arrest, low output syndrome, acute cardiac failure, intra-aortic balloon pump, or
multiorgan failure.
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649in the PLF group. When we compared patients
experiencing at least one cardiac event among acute
ischemic events, cardiac arrest, low output syn-
drome, acute cardiac failure, intra-aortic balloon
pump use, and multiorgan failure, incidence of this
composite event was higher (p < 0.0001) in LEF and
PLF groups than in the NF group (Table 2). Non-
cardiac events and cardiac enzyme levels were
similar among groups (all p > 0.07). Patients with
LEF had slightly but signiﬁcant longer hospital
length of stay (p ¼ 0.04) than NF patients (Table 2).
Prolonged use of inotropic support was signiﬁcantly
elevated in the LEF and PLF groups than in NF
patients.
PREDICTORS OF MID-TERM SURVIVAL. During a
follow-up of 4.1  3.0 years, there were 241
deaths (21%). Five-year survival rates were lower
(p < 0.0001) in LEF and PLF groups than in the NF
group (72  4% and 81  2% vs. 85  2%, respectively)
(Figure 3). In univariate analysis, signiﬁcant pre-
operative predictors of mortality were older age
(p < 0.0001), NYHA functional class III or IV
(p < 0.0001), atrial ﬁbrillation (p ¼ 0.0006), chronic
kidney failure (p < 0.0001), diabetes (p ¼ 0.001),
coronary artery disease (p ¼ 0.0004), Duke myocar-
dial jeopardy score (p ¼ 0.0004), chronic obstructive
pulmonary disease (p ¼ 0.0001), higher LV mass
index (p ¼ 0.02), lower peak aortic jet velocity
(p ¼ 0.005), lower mean gradient (p ¼ 0.003), lower
SVi (p < 0.0001), lower LVEF (p < 0.0001), LEF group
(p < 0.0001), and PLF group (p ¼ 0.03) (Table 4). The
factors independently associated with increased risk
of mortality were older age (p < 0.0001), NYHA
functional class III or IV (p ¼ 0.005), chronic kidney
failure (p ¼ 0.002), Duke myocardial jeopardy score
(p ¼ 0.03), diabetes (p ¼ 0.02), and LEF group
(p ¼ 0.01) or lower LVEF (p ¼ 0.02) (Table 4, Central
Illustration). PLF group or SVi did not remain associ-
ated with mid-term mortality in the multivariate
analysis (p ¼ 0.11 and p ¼ 0.12, respectively) (Central
Illustration).
In all models, mean gradient could be replaced by
peak aortic jet velocity or aortic valve area without
impact on the results. Similar to mean gradient, peak
aortic jet velocity or aortic valve area were not inde-
pendently associated with mortality (all p > 0.81 or
p > 0.26, respectively). Among patients with LEF,
low ﬂow (e.g., SVi #35 ml ∙ m2) and low gradient
(<40 mm Hg or #20 mm Hg) were not independent
predictors of higher mortality (all p $0.13).
If the analysis was restricted to patients who un-
derwent an isolated AVR or an AVR and CABG, the
results were similar with an independent impact
of LEF group or LVEF on long-term mortality (allp < 0.05), and there was no independent association
between PLF group or SVi and mid-term mortality
(all p > 0.27) (Online Appendix).
DISCUSSION
There are 3 main ﬁndings of this study. 1) Patients
with LEF and PLF have increased 30-day mortality
compared to NF patients. 2) The 30-day mortality
excess observed in LEF patients was entirely captured
by the operative risk score. On the other hand, PLF
remained independently associated with increased
risk of 30-day mortality, even after adjustment for
operative risk score. 3) Beyond 30 days, the mortality
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650risk continued to be higher in LEF than in NF patients
but was similar in PLF and NF patients (Central
Illustration).
It is well known that low LVEF is a powerful
independent predictor of mortality after AVR, and
this factor was therefore included in the calculation
of operative risk scores (9–11). Thus, it is not sur-
prising that LVEF and LEF group were not found
to be independent predictors of 30-day mortality
after adjustment for operative risk score (e.g., Par-
sonnet risk score). LVEF also was found to be a
powerful independent predictor of mid-term mor-
tality in this study, as well as in previous studies in
AS patients undergoing AVR (12,13). Low preopera-
tive LVEF may reﬂect a more advanced stage of
myocardial ﬁbrosis and dysfunction (14,15). Hence,and Multivariate Predictors of 30-Day Mortality
Increment
Univariable Analysis
Odds Ratio 95% CI p Value Odds R
1 yr 1.05 1.02–1.09 0.007 —
Female 2.58 1.41–4.84 0.002 2.8
1 point 1.08 1.05–1.11 <0.0001 1.0
Yes 3.91 2.04–8.00 <0.0001 3.13
1 point increase 1.14 1.06–1.22 0.0003 1.10
5 mm Hg increase 0.90 0.80–0.99 0.04 —
5 ml ∙ m2 decrease 1.43 1.18–1.74 0.0003 —
5% decrease 1.16 1.05–1.27 0.003 —
0.0003
Referent — — — —
3.78 1.67–8.75 0.002 —
3.76 1.81–8.22 0.0004 2.9
pendent predictors of mortality (i.e., statistically signiﬁcant in multivariable analysis).
LVEF ¼ left ventricular ejection fraction; SVi ¼ stroke volume index; other abbreviations as ia substantial proportion of patients with LEF may
have irreversible myocardial impairment and may
thus not improve their LV function and symptoms
following successful AVR, thereby explaining the
continued mortality excess observed in this subset
during the late postoperative phase. Additional im-
aging biomarkers, such as LV ﬂow reserve, assessed by
dobutamine stress echocardiography or extent of
myocardial ﬁbrosis assessed by late gadolinium
enhancement or T1-weighted mapping cardiac mag-
netic resonance could be helpful in improving patient
risk stratiﬁcation and selection for AVR in this chal-
lenging subset of patients (14–17). Conversely,
reduced SVi and PLF groups were independently
associated with 30-day mortality but not with late
mortality (Central Illustration). Although several of the
features of PLF (e.g., pronounced LV concentric
remodeling and/or hypertrophy, moderate to severe
diastolic dysfunction, decreased longitudinal strain,
and reduced SVi) are associated with increased oper-
ative mortality, they often improve within the weeks
or months following a successful surgical or trans-
catheter AVR (18–22). This may explain the fact that
PLF has no impact on late postoperative mortality.
Low pre-procedural SVi has been shown to be an in-
dependent predictor of procedural and/or 2-year
mortality after transcatheter AVR, whereas low LVEF
was not (2,3). Discrepancies between these results and
those of the present study regarding the impact on
late mortality could be explained by differences in the
type of procedure (e.g., transcatheter versus surgical
AVR), baseline risk proﬁle of the study population,
and follow-up duration (2 vs. 4 years). Interestingly,
a post-hoc analysis of the PARTNER-I (Placement ofModel 1 Model 2
atio 95% CI p Value Odds Ratio 95% CI p Value
— 0.49 — — 0.44
1 1.42–5.73 0.003 2.82 1.41–4.78 0.004
5 1.01–1.09 0.002 1.04 1.01–1.08 0.003
1.58–6.59 0.0009 2.96 1.48–6.26 0.002
1.01–120 0.03 1.10 1.01–1.20 0.03
— 0.26 — — 0.34
— — 1.18 1.01–1.36 0.05
— — — — 0.82
0.02
— — — — —
— 0.28 — — —
7 1.40–6.60 0.004 — — —
n Table 1.


































PLF group vs. NF group: HR=1.42; p=0.03
p*=0.28















Kaplan-Meier curves of overall survival in normal ﬂow (red solid line), paradoxical low ﬂow
(blue dot line), and low ejection fraction (orange dash-dot line) patients. *Adjusted for age,
female sex, New York Heart Association functional class III or IV, atrial ﬁbrillation, chronic
kidney failure, diabetes, coronary artery disease, chronic obstructive pulmonary disease,
LV mass index, and mean gradient. LV ¼ left ventricular; HR ¼ hazard ratio.
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651Aortic Transcatheter Valves) trial (3) revealed that PLF
is associated with increased mortality following both
types of procedures, but 1-year survival was signiﬁ-
cantly better with transcatheter AVR than with sur-
gical AVR. This early survival beneﬁt associated with
transcatheter AVR in patients with PLF may be, at
least in part, due to the better hemodynamics and
lower incidence of severe prosthesis-patient
mismatch achieved by this procedure than surgical
AVR (23,24), as well as to its less invasive nature.
These ﬁndings suggest that transcatheter AVR may be
superior to surgical AVR in this particular subset of
patients, but more data are needed to further support
this hypothesis.
Low pre-procedural mean gradient also has been
associated with increased mortality after surgical (11)
or transcatheter AVR (25,26). However, recent studies
revealed that this association was, in large part,
explained by the presence of low ﬂow (2,3). Accord-
ingly, in the present study, association between low
mean gradient or low peak aortic jet velocity and
mortality was no longer signiﬁcant after adjustment
for SVi and LVEF.
STUDY LIMITATIONS. The most important limitation
of this study is the small number of operative deaths
that may not allow identiﬁcation of all independent




Age, yrs 1.04 1.03–1.06
Female — —
NYHA functional class III to IV 2.03 1.57–2.64
Atrial ﬁbrillation 1.88 1.33–2.59
Chronic kidney failure 1.98 1.42–2.70
Diabetes 1.55 1.18–2.01
Coronary artery disease 1.61 1.24–2.12
Duke Myocardial Jeopardy Score 1.06 1.03–1.09
COPD 1.82 1.35–2.41
Concomitant CABG — —
LV mass index, 10 g ∙ m2 ∙ kg 1.04 1.01–1.08
Peak aortic jet velocity, m ∙ s1 increase 0.79 0.66–0.93
Mean gradient, 5 mm Hg increase 0.93 0.90–0.98
Stroke volume index, 5 ml ∙ m2 decrease 1.18 1.09–1.27





Bold variables are the independent predictors of mortality (i.e. statistically signiﬁcant in
CABG ¼ coronary arteries bypass graft; COPD ¼ chronic obstructive pulmonary diseasthe important differences in baseline characteristics
among groups, especially between LEF and the other
groups, we cannot exclude the possibility of residualsis
Multivariate Analysis
Model 1 Model 2
p Value HR 95% CI p Value HR 95% CI p Value
<0.0001 1.04 1.02–1.06 <0.0001 1.04 1.02–1.06 <0.0001
0.19 — — 0.35 — — 0.35
<0.0001 1.51 1.13–2.02 0.005 1.50 1.12–2.01 0.006
0.0006 — — 0.20 — — 0.24
<0.0001 1.78 1.23–2.51 0.002 1.80 1.24–2.54 0.002
0.001 1.44 1.07–1.92 0.02 1.42 1.06–1.90 0.02
0.0004 — — — — — —
0.0004 1.04 1.01–1.08 0.03 1.04 1.01–1.07 0.04
0.0001 — — 0.15 — — 0.13
0.31 — — — — — —
0.02 — — 0.17 — — 0.16
0.005 — — — — — —
0.003 — — 0.46 — — 0.50
<0.0001 — — — — — 0.12
<0.0001 — — — 2.24 1.13–4.38 0.02
<0.0001 0.03 — — —
Reference — — —
<0.0001 1.52 1.09–2.11 0.01 — — —
0.03 — — 0.11 — — —
multivariable analysis).
e; EF ¼ ejection fraction; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 3.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
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652confounding in the logistic regression and Cox
models. Our results need to be conﬁrmed in larger,
prospective studies.
Despite the fact that data were prospectively
collected, they were retrospectively analyzed. How-
ever, our design, routine clinical practice, and inter-
rogation of the central Quebec Institute of Statistics
database limited enrollment and follow-up bias.
Data for myocardial strain or dobutamine stress
echocardiography were not available in this cohort
despite their potentially great interest.Low transvalvular ﬂow occurs in 15% to 35% of
patients with aortic valve stenosis regardless of
LVEF. Low ﬂow is associated with increased mortality
early AVR surgery, even in patients with preserved
EF, but is not predictive of later postoperative
mortality.
COMPETENCY IN PATIENT CARE: Stroke volume
index should be considered in addition to LVEF in
assessment of early and long-term mortality risks
associated with AVR surgery.
TRANSLATIONAL OUTLOOK: Further studies are
needed to evaluate the relative advantages and
disadvantages of transcatheter and surgical AVR in
patients with low ﬂow aortic stenosis stratiﬁed
according to LVEF.CONCLUSIONS
In this series of patients with severe AS who under-
went AVR, patients with PLF or LEF AS had higher
operative risk. However, the association between LEF
and lower LVEF with operative mortality was no
longer signiﬁcant after adjustment for operative risk
score, whereas PLF or low SVi remained independent
predictors of mortality even after adjustment for risk
score. LEF and lower LVEF were independent pre-
dictors of mid-term mortality, whereas PLF or low SVi
were not. Consideration of SVi may be useful to
enhance operative risk stratiﬁcation prior to AVR and
improve decision making between surgical and
transcatheter AVR. Further studies are needed to
determine whether outcomes of patients with PLF are
better with transcatheter AVR or surgical AVR.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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